Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Avacopan is a complement 5a receptor antagonist and a cytochrome P450 3A4 inhibitor.
Read the full article on WikipediaAnti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis Clinical criteria: Treatment Phase: Induction treatment The condition must be severe granulomatosis with polyangiitis; OR The condition must be severe microscopic polyangiitis, AND The condition must be active at the time of the first prescription for this drug per treatment cycle, AND Patient must have ANCA associated vasculitis that is either: (i) organ-threatening, (ii) life-threatening disease, AND Patient must be undergoing concomitant therapy with at least another drug therapy as part of a regimen specified in this drug's approved Product Information, AND Patient must not receive more than 12 months of PBS-subsidised treatment with this drug per induction. A prescriber may apply for more than one induction treatment for their patient
Working under the parallel aged-care framework? Aged-care equivalent →